Dynamic Changes in Circulating Tumor Fraction as a Predictor of Real-World Clinical Outcomes in Solid Tumor Malignancy Patients Treated with Immunotherapy
Oncology and Therapy · 2024-09 · 12 (3) · 509-524
DOI: 10.1007/s40487-024-00287-2 ↗Kurz gefasst
Fachartikel in der Zeitschrift Oncology and Therapy, online erschienen am 22.07.2024. Verfasst von Ryan D Gentzler und 21 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology and Oncology, University of Virginia, Charlottesville, VA, USA. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Tempus.
Abstract (Originalsprache)
INTRODUCTION: A dynamic molecular biomarker that can identify early efficacy of immune checkpoint inhibitor (ICI) therapy remains an unmet clinical need. Here we evaluate if a novel circulating tumor DNA (ctDNA) assay, xM, used for treatment response monitoring (TRM), that quantifies changes in ctDNA tumor fraction (TF), can predict outcome benefits in patients treated with ICI alone or in combination with chemotherapy in a real-world (RW) cohort. METHODS: This retrospective study consisted of patients with advanced cancer from the Tempus de-identified clinical genomic database who received longitudinal liquid-based next-generation sequencing. Eligible patients had a blood sample ≤ 40 days prior to the start of ICI initiation and an on-treatment blood sample 15-180 days post ICI initiation. TF was calculated via an ensemble algorithm that utilizes TF estimates derived from variants and copy number information. Patients with molecular response (MR) were defined as patients with a ≥ 50% decrease in TF between tests. In the subset of patients with rw-imaging data between 2 and 18 weeks of ICI initiation, the predictive value of MR in addition to rw-imaging was compared to a model of rw-imaging alone. RESULTS: The evaluable cohort (N = 86) was composed of 14 solid cancer types. Patients received either ICI monotherapy (38.4%, N = 33) or ICI in combination with chemotherapy (61.6%, N = 53). Patients with MR had significantly longer rw-overall survival (rwOS) (hazard ratio (HR) 0.4, P = 0.004) and rw-progression free survival (rwPFS) (HR 0.4, P = 0.005) than patients with molecular non-response (nMR). Similar results were seen in the ICI monotherapy subcohort; HR 0.2, P = 0.02 for rwOS and HR 0.2, P = 0.01 for rwPFS. In the subset of patients with matched rw-imaging data (N = 51), a model incorporating both MR and rw-imaging was superior in predicting rwOS than rw-imaging alone (P = 0.02). CONCLUSIONS: xM used for TRM is a novel serial quantitative TF algorithm that can be used clinically to evaluate ICI therapy efficacy.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Hematology and Oncology, University of Virginia, Charlottesville, VA, USA.
- Tempus AI, Inc., 600 West Chicago Avenue, Suite 510, Chicago, IL, 60654, USA.
- Division of Hematology/Oncology, Vanderbuilt-Ingram Cancer Center, Nashville, TN, USA.
- Hematology Oncology, John Hopkins Bayview Medical Center, Baltimore, MD, USA.
- Tempus AI, Inc., 600 West Chicago Avenue, Suite 510, Chicago, IL, 60654, USA. rotem.benshachar@tempus.com.
- Department of Medicine, Northwestern University, Evanston, IL, USA.
Förderung
- Tempus
Zitieren
APA
Gentzler, R. D., Guittar, J., Mitra, A., Iams, W. T., Driessen, T., Schwind, R., Stein, M. M., Kaneva, K., Hyun, S. W., Liu, Y., Dugan, A. J., Vibat, C. R. T., Sangli, C., Freaney, J., Rivers, Z., Feliciano, J. L., Lo, C., Sasser, K., Ben-Shachar, R., …, & Chaudhuri, A. A. (2024). Dynamic Changes in Circulating Tumor Fraction as a Predictor of Real-World Clinical Outcomes in Solid Tumor Malignancy Patients Treated with Immunotherapy. Oncology and Therapy, 12(3), 509-524. https://doi.org/10.1007/s40487-024-00287-2
Vancouver
Gentzler RD, Guittar J, Mitra A, Iams WT, Driessen T, Schwind R, et al. Dynamic Changes in Circulating Tumor Fraction as a Predictor of Real-World Clinical Outcomes in Solid Tumor Malignancy Patients Treated with Immunotherapy. Oncology and Therapy. 2024;12(3):509-524. doi:10.1007/s40487-024-00287-2
BibTeX
@article{Gentzler2024,
author = {Gentzler, Ryan D and Guittar, John and Mitra, Akash and Iams, Wade T and Driessen, Terri and Schwind, Regina and Stein, Michelle M and Kaneva, Kristiyana and Hyun, Seung Won and Liu, Yan and Dugan, Adam J and Vibat, Cecile Rose T and Sangli, Chithra and Freaney, Jonathan and Rivers, Zachary and Feliciano, Josephine L and Lo, Christine and Sasser, Kate and Ben-Shachar, Rotem and Nimeiri, Halla and Patel, Jyoti D and Chaudhuri, Aadel A},
title = {Dynamic Changes in Circulating Tumor Fraction as a Predictor of Real-World Clinical Outcomes in Solid Tumor Malignancy Patients Treated with Immunotherapy},
journal = {Oncology and Therapy},
year = {2024},
volume = {12},
number = {3},
pages = {509--524},
doi = {10.1007/s40487-024-00287-2}
}
EUVIMED